Skip to main content
Retour
PODD logo

Insulet Corporation

Qualité des données : 100%
PODD
NASDAQ Healthcare Medical - Devices
218,11 €
▲ 2,11 € (0,98%)
Cap. Boursière : 15,35B
Fourchette du Jour
215,62 € 221,11 €
Fourchette 52 Semaines
215,62 € 354,88 €
Volume
1 040 242
Moyenne 50J / 200J
253,15 € / 297,10 €
Clôture Précédente
216,00 €

Quick Summary

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (631 pairs)

Métrique Action Médiane du Secteur
P/E 62,1 0,2
P/B 10,1 3,0
ROE % 18,1 3,5
Net Margin % 9,1 3,8
Rev Growth 5Y % 25,3 9,7
D/E 0,7 0,2

Objectif de Cours des Analystes

Hold
357,25 € +63.8%
Low: 286,00 € High: 435,00 €
P/E Prévisionnel
34,09
BPA Prévisionnel
6,34 €
Croissance BPA (est.)
+0,0%
CA Est.
3,31B

Estimations de Bénéfices

Période BPA Est. CA Est. Analystes
FY2030 14,53 €
13,75 € – 14,90 €
6,14B 5
FY2029 12,78 €
12,10 € – 13,11 €
5,52B 2
FY2028 10,20 €
9,98 € – 10,70 €
4,68B 7

Earnings Surprises

Last 8 quarters
Quarter Est. EPS Actual EPS Surprise
2026-02-18 1,48 € 1,55 € +4,7%
2025-11-06 1,14 € 1,24 € +8,8%
2025-08-07 0,92 € 1,17 € +27,2%
2025-05-08 0,79 € 1,02 € +29,1%
2025-02-20 1,00 € 1,15 € +15,0%
2024-11-07 0,76 € 0,90 € +18,4%
2024-08-08 0,56 € 0,55 € -2,5%
2024-05-09 0,39 € 0,73 € +87,2%

Dividend History

Yield

0,00%

Payout Ratio

0,00%

Growth (3Y)

N/A

Growth (5Y)

N/A

No dividend history available.

Points Clés

Revenue grew 25,30% annually over 5 years — strong growth
Earnings declined -40,93% over the past year
ROE of 18,12% — decent returns on equity
Generating 377,70M in free cash flow
P/E of 62,14 — premium valuation
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 5,43%

Croissance

Revenue Growth (5Y)
25,30%
Revenue (1Y)30,73%
Earnings (1Y)-40,93%
FCF Growth (3Y)132,12%

Qualité

Return on Equity
18,12%
ROIC13,85%
Net Margin9,12%
Op. Margin17,50%

Sécurité

Debt / Equity
0,69
Current Ratio2,78
Interest Coverage5,94

Valorisation

P/E Ratio
62,14
Forward P/E34,09
P/B Ratio10,13
EV/EBITDA33,11
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 30,73% Revenue Growth (3Y) 26,32%
Earnings Growth (1Y) -40,93% Earnings Growth (3Y) 9,44%
Revenue Growth (5Y) 25,30% Earnings Growth (5Y) 95,84%
Profitability
Revenue (TTM) 2,71B Net Income (TTM) 247,10M
ROE 18,12% ROA 7,75%
Gross Margin 71,63% Operating Margin 17,50%
Net Margin 9,12% Free Cash Flow (TTM) 377,70M
ROIC 13,85% FCF Growth (3Y) 132,12%
Safety
Debt / Equity 0,69 Current Ratio 2,78
Interest Coverage 5,94
Dividends
Dividend Yield 0,00% Payout Ratio 0,00%
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio 62,14 Forward P/E 34,09
P/B Ratio 10,13 P/S Ratio 5,67
PEG Ratio -1,96 Forward PEG N/A
EV/EBITDA 33,11 Fwd EV/EBITDA 28,81
Forward P/S 4,64 Fwd Earnings Yield 2,93%
FCF Yield 2,46%
Market Cap 15,35B Enterprise Value 15,69B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 2,71B 2,07B 1,70B 1,31B 1,10B
Net Income 247,10M 418,30M 206,30M 4,60M 16,80M
EPS (Diluted) 3,48 5,78 2,94 0,07 0,25
Gross Profit 1,94B 1,45B 1,16B 805,60M 752,10M
Operating Income 473,80M 308,90M 220,00M 37,60M 126,00M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 3,19B 3,09B 2,59B 2,25B 2,05B
Total Liabilities 1,68B 1,88B 1,86B 1,77B 1,49B
Shareholders' Equity 1,52B 1,21B 732,70M 476,40M 556,30M
Total Debt 1,05B 1,42B 1,45B 1,43B 1,29B
Cash & Equivalents 716,10M 953,40M 650,70M 623,90M 791,60M
Current Assets 1,89B 1,87B 1,57B 1,30B 1,32B
Current Liabilities 680,10M 528,40M 451,20M 364,70M 228,80M